Comments on draft hepatitis federal implementation plan

We cannot achieve the goal of ending hepatitis without increased funding for the key elements of the strategy, including testing, treating, and vaccination. Increasing resources for hepatitis elimination must be our first priority. While this draft hepatitis federal implementation plan was drafted with current resources in mind, there are areas where we would suggest some strengthening.

read more

Letter in support of holding a hearing on Michigan HB 4353

The HIV+Hepatitis Policy Institute strongly supports Michigan House Bill 43534, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums and ask that you conduct a hearing on the bill as soon as possible.

read more

Testimony on Senate FY22 appropriations for HIV and hepatitis programs

As our country continues to respond and recover from the COVID-19 pandemic, which has impacted HIV and hepatitis services, we know we have the science to end two other infectious diseases that have been impacting our country for decades: HIV and hepatitis C. While there still is no cure or vaccine for HIV, we have preventive tools along with treatments that suppress the virus, and together can bring the number of new infections down to a point that we can end HIV.

read more

Letter to Tamara Jensen on Medicare NCD Update for Hepatitis C Screening

The HIV+Hepatitis Policy Institute and others are requesting that CMS update the HCV screening National Coverage Determination to bring it in line with the 2020 U.S. Preventive Services Task Force recommendation for HCV screening. The current coverage determination only requires Medicare coverage for HCV screening of baby boomers and people at high risk. We are requesting that Medicare should cover screening of everyone between the ages of 18-79, regardless of symptoms or risk group.

read more

Pin It on Pinterest